Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Therapy in Biliary Atresia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 0-180 days old~* Diagnosed with biliary atresia through liver biopsy and/or intra-operative cholangiogram~* No previous Kasai portoenterostomy performed at another institution~* Able to take medications orally~* Legal guardian signs consent after understanding risks and investigational nature of study~Exclusion Criteria:~* Infants greater than 180 days old~* Infants receiving a Kasai portoenterostomy at another institution~* Infants unable to take medications orally

- Gender: ALL
- Minimum Age: None
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes.

Based on this trial design, predict the completion outcome and termination type (if applicable).